Wednesday, March 28, 2012

If You Have Stock In Health Insurance Companies

Sell now! One of the untold stories of ObamaCare is how the insurance companies convinced Democrats to write the law in a way that is greatly to their benefit. And it was such a good deal for Big Pharmaceutical that it paid its lobbyist, for congressman Billy Tauzin nearly $12 million for the deal he cut for them with Obama. ObamaCare's passage also sent Health insurance company stock prices soaring. Clearly, this was a good deal for them too.
 Healthcare interest groups spent tens of millions of dollars cutting deals with the Obama administration and Congress in 2009 and 2010. The Supreme Court may soon leave those deals in tatters—and saddle the healthcare industry with multi-billion dollar losses.

Industry insiders have been following the first two days of the high court’s consideration of the law, but the debate over severability may be the most important yet for the interests of pharmaceutical and healthcare giants.

If the court rules that the individual mandate, which requires every American to purchase health insurance or pay a costly “tax penalty,” is unconstitutional, it can still choose to uphold the remainder of the law.

But that would be an expensive decision for drug companies, according to business intelligence firm Global Data, which estimates that “the pharmaceutical industry … may lose out on $115 billion in additional revenue over the next decade if the law is overturned.”
It would serve them right for getting into bed with these vipers.


Post a Comment

Subscribe to Post Comments [Atom]

Links to this post:

Create a Link

<< Home